Table 3.
Evolution of eGFR, proteinuria and haematuria in all patients (N = 25)
| Characteristics | –12 months | Baseline | 1 month | 3 months | 6 months | 12 months | Last visit with CS + MPAA treatment |
|---|---|---|---|---|---|---|---|
| eGFR (mL/min/1.73 m2), median (IQR) | 80.7 (60–99)*** | 48.7 (34–67) | 49.4 (36.8–75.0) | 58.0 (40.5–84.0)* | 59.8 (36.1–92.5)** | 65.0 (36.0–92.0)** | 64.0 (33.4–90.0)* |
| Proteinuria (g/day), median (IQR) | 0.8 (0–2.0) | 1.8 (1.0–2.5) | 1.4 (0.9–2.5) | 1.0 (0.6–1.3)*** | 0.6 (0.4–1.1)*** | 0.5 (0.3–0.8)*** | 0.6 (0.3–1.2)*** |
| Patients with haematuria, n (%) | 25 (100) | 25 (100) | 25 (100) | 22 (88.0) | 16 (64.0)* | 15 (60.0)*** | 15 (60.0)*** |
*P < 0.05, **P < 0.01 and ***P < 0.001 with respect to baseline values.